Using an optimal cut-off point of 873 (95% confidence interval (CI) = 0.69–0.87) revealed that serum epiplakin levels exhibited 68.3% sensitivity and 79.2% specificity for BC. This evidence concerns the gene EPPK1 and breast cancer.